Add BrightSurf on Google Email

Ludwig study extends potential for personalized immunotherapy to large variety of cancers

Researchers developed a new method to identify highly reactive killer T cells in ovarian tumors, showing they can be selectively grown for personalized cell-based immunotherapies. The approach overcomes limitations of existing methods, enabling the use of tumor-infiltrating lymphocytes for treating low-mutational load tumors.

SourceLudwig Institute for Cancer Research·JournalNature Communications·DateMar 15, 2018

New biomarkers predict outcome of cancer immunotherapy

Researchers identified biomarkers in blood samples that predict response to immunotherapy, allowing for personalized treatment decisions. High-dimensional cell analysis and computer-aided pattern recognition enabled the detection of subtle immune responses and molecular patterns associated with therapy success.

SourceUniversity of Zurich·JournalNature Medicine·DateJan 9, 2018

Omalizumab improves efficacy of oral immunotherapy for multiple food allergies

A new clinical trial shows that combining omalizumab with oral immunotherapy increases the ability of children with multiple food allergies to safely consume allergenic foods. The treatment resulted in over 80% of children being able to eat at least two grams of two or more foods without adverse reactions.

SourceNIH/National Institute of Allergy and Infectious Diseases·JournalThe Lancet Gastroenterology & Hepatology·DateDec 11, 2017

First line combination therapy improves progression-free survival in advanced lung cancer

The combination of chemotherapy and immunotherapy significantly improves progression-free survival in patients with advanced non-squamous NSCLC. The study showed that the addition of atezolizumab to bevacizumab and chemotherapy leads to a median PFS of 8.3 months, compared to 6.8 months with bevacizumab and chemotherapy alone.

SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·DateDec 7, 2017

DNA mutations shed in blood predicts response to immunotherapy in patients with cancer

A study by University of California San Diego School of Medicine researchers reveals that a simple blood test can predict which patients will respond to checkpoint inhibitor-based immunotherapies, with 45% of patients showing significant response. The findings suggest that patients with high numbers of genomic alterations in their tumo...

SourceUniversity of California - San Diego·JournalClinical Cancer Research·DateOct 2, 2017

Discovery could guide immunotherapy for lung cancer

Scientists have discovered a new type of immune cell that can predict which lung cancer patients will benefit from immunotherapy treatment. The study found that patients with high levels of tissue-resident memory T-cells in their tumour were more likely to survive, and the cells' behaviour played a key role in increasing survival rates.

SourceCancer Research UK·JournalNature Immunology·DateJun 19, 2017

Immunotherapy against bee stings in some cases incomplete

Researchers found that commercial preparations for allergy shots often lack sufficient levels of key allergens, which could affect treatment success. Customized immunotherapy tailored to individual patients' reactions is a promising approach, but its development is still in its infancy.